BioLineRx to Report 2024 Annual Results on March 31, 2025
Rhea-AI Summary
BioLineRx (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, has announced it will release its audited financial results for the year ended December 31, 2024, on Monday, March 31, 2025, before U.S. markets open.
The company will host a conference call at 8:30 a.m. EDT featuring CEO Philip Serlin. Investors can access the call via:
- U.S. dial-in: +1-888-281-1167
- International dial-in: +972-3-918-0685
Positive
- None.
Negative
- None.
News Market Reaction – BLRX
In the trading session that priced this news, BLRX declined 4.47%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Management to Hold Conference Call at 8:30 a.m. EDT

The Company will host a conference call at 8:30 a.m. EDT featuring remarks by Philip Serlin, Chief Executive Officer.
To access the conference call, please dial +1-888-281-1167 from the
About BioLineRx
BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The company's first approved product is APHEXDA® (motixafortide) with an indication in the
Learn more about who we are, what we do, and how we do it at www.biolinerx.com, or on Twitter and LinkedIn. and events.
CONTACTS:
Irina Koffler
LifeSci Advisors, LLC
ikoffler@lifesciadvisors.com
Moran Meir
LifeSci Advisors, LLC
moran@lifesciadvisors.com
Logo: https://mma.prnewswire.com/media/2154863/BioLineRx_Ltd_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/biolinerx-to-report-2024-annual-results-on-march-31-2025-302409115.html
SOURCE BioLineRx Ltd.